Policy & Regulation
Vibe Bio Launches to Transform Drug Development for Patients with Rare Diseases
22 June 2022 - - US-based biotechnology company Vibe biotechnology Inc has closed USD 12m in funding to advance its community-driven approach to identifying and developing treatments for rare diseases, the company said.

By leveraging a decentralized autonomous organization, Vibe Bio builds a global community of patients, scientists, and partners around a shared mission to cure rare diseases.

The company's novel approach seeks to scale the development of treatments sustainably and provides patient communities unprecedented ownership over the results.

Vibe Bio's DAO will serve as an online coordination hub for its diverse stakeholders, connecting patient communities directly to investors, scientists, and other experts.

Members will have the power to vote on which rare disease research proposals, as well as nominate specific diseases or candidate medicines, to pursue through its USDVIBE governance token.

The proposals will each be vetted by scientists and financial experts.

Vibe Bio has already partnered with two patient advocacy organizations to launch and fund independent biotechnology companies to pursue promising therapeutics for rare and often fatal diseases.

With Chelsea's Hope, a patient advocacy organization dedicated to curing Lafora disease, which is a fatal form of progressive myoclonus epilepsy that presents in children and adolescents, Vibe Bio is launching New Hope Therapeutics.

Vibe Bio has also partnered with NF2 Biosolutions, a patient advocacy organization accelerating gene therapy research for Neurofibromatosis Type 2, a disorder characterized by the growth of noncancerous tumors in the nervous system, to launch Merlin Therapeutics.

The intellectual property from the ventures will be owned by the independent biotechnology companies.

According to the National Institutes of Health, there are approximately 7,000 rare diseases that, in total, affect between 25 and 30 m or nearly 1 in 10 Americans.

Half of all rare disease patients are children, and only 30 % of those children will live to see their fifth birthday.

Tayi and co-founder Joshua Forman founded Vibe Bio after Tayi's daughter was born with a disease that, while well understood, lacked therapeutic options for treatment.

After spending a considerable amount of time in the NICU, Tayi worked to develop a different approach to developing therapeutics one that taps new sources of capital from the cryptocurrency world and empowers the patients who would benefit most from new therapies.

Vibe Bio has raised USD 12m in financing from some of the industry's leading institutions and angel investors.

Initialized Capital led the round with participation from Naval Ravikant, Balaji Srinivasan, 6th Man Ventures, Yvonne Hao, Enke Bashllari, Andy Coravos, Lerer Hippeau, Andy Palmer, and others.

Unlike a traditional company, Vibe Bio's assets and financing will be informed by its community and its governance token USDVIBE, which will be launched later this year.

All interested parties, including patients, drug developers, and investors, are encouraged to visit Vibe Bio's website for more information.


Related Headlines